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ABSTRACT: Advanced drug delivery systems (DDS) enhance treatment efficacy of
different therapeutics in a dosage, spatial, and/or temporal controlled manner. To date,
numerous chemical- or physical-based stimuli-responsive formulations or devices for
controlled drug release have been developed. Among them, the emerging mechanical
force-based stimulus offers a convenient and robust controlled drug release platform and
has attracted increasing attention. The relevant DDS can be activated to promote drug
release by different types of mechanical stimuli, including compressive force, tensile force,
and shear force as well as indirect formats, remotely triggered by ultrasound and magnetic
field. In this review, we provide an overview of recent advances in mechanically activated
DDS. The opportunities and challenges regarding clinical translations are also discussed.
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1. INTRODUCTION
Drug delivery systems (DDS) are of paramount importance to
enhance the treatment efficacy of medications.1−4 The last two
decades have witnessed great progress in sustained drug
delivery.5−11 Nevertheless, there are many clinical situations
requiring more than a zero-ordered, continuous drug release
profile, but an on-demand control of therapeutics. Dosage-,
spatial-, and temporal-controllable drug release, which can target
diseased tissue, enhance uptake efficiency, prolong action time,
and improve bioavailability of agents, has been heavily pursued in
recent years.12−22 Such DDS can respond to either endogenous
environmental conditions, including pH,23−28 redox,29−32
hypoxia,33−35 ATP,36−39 glucose,40−43 and enzymes,44−50 or
exogenous signals such as temperature,51−53 light,54−57 magnetic
field,58−61 and electric current.62−64
Mechanical force, with a subclassification of compressive,
tensile, and shear forces (Figure 1a),65,66 is ubiquitously achieved
in the body or easily applied externally.67 Force sources range
from intrinsic compression/stretching via joint movements to
internal shear force in vascular systems, as well as exterior
acoustic and magnetic force remotely applied through the skin
(Figure 1b). Easy access of mechanical stimuli facilitates
treatment in a variety of conditions with convenient commands.
Especially in occasions of emergence, such as heart attack and
hypoglycemia, the mechanical force-mediated trigger could
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enable prompt delivery of therapeutics by patients in a self-
administered manner. Moreover, compared to chemical or
biological triggers, application of mechanical force provides a
relatively predictable control in direction and an adjustable
magnitude management toward precision release of therapeutics.
In addition, patient-controlled drug delivery may potentially
increase patient satisfaction compared with intermittent
administration, since the patients themselves can conveniently
regulate the release dosage and timing of the drug.
Collectively, mechanical force is a promising candidate to
realize controlled drug release.67,68 To be specific, the
compressive and tensile forces can be readily obtained by using
hands or from simple daily motions, such as tension in muscles,
tendons, and bone joints, as well as compression in cartilage and
bones.69 Therefore, DDS integrated with mechanoresponsive
modality offers self-administration therapy without requiring
additional instruments, while the shear force generated by blood
flow in vascular systems70 holds promise for noninvasive
Figure 1. Different forms of mechanical force. (a) Three main types of mechanical force. (b) Mechanical force can be typically obtained in the human
body or induced externally by ultrasound or magnetic field.
Figure 2. Schematic illustration of diverse mechanical force-triggered drug delivery systems. (a) Compressive or tensile force can induce drug release. (i)
Physically loaded drugs can be released by deformation of carriers under compression. (ii) Tensile force can deform mechanoresponsive particles
embedded in the matrices and release the encapsulated drugs. (iii) Materials can be degraded upon exposure to related enzymes under strain. (iv)
Compressive force can break the chemical bond. (b) Drug release can be triggered by shear force caused by (i) dissociation of aggregates or (ii)
deformation of particles. (c) Ultrasound can facilitate drug release by cavitation or radiation. (d) External magnetic field can trigger drug release by
deforming ferrogels.
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cardiovascular drug delivery.71,72 The design features of
formulations or devices based on the two directly interacting
triggers generally involve physical deformation or mechano-
chemical changes of drug carriers. On the other hand, ultrasound,
as a highly efficient and noninvasive trigger, has been widely
explored in the drug delivery field. The longitudinal force
produced by ultrasound can induce hyperthermia, cavitation, and
radiation, resulting in destruction of drug carriers and drug
release by either thermal or nonthermal functions.73−75 Addi-
tionally, magnetic force induced by a magnetic field can activate
the magnetoresponsive components. Integrated with thermo-
sensitive materials or flexible matrices, the activated magneto-
responsive particles can achieve a controlled release of cargoes by
disassociation or morphology variation.76
This review surveys the mechanical force-triggered DDS,
mainly classified as direct interaction forces, including
compressive, tensile, and shear forces as well as induced forces
generated by other stimuli like ultrasound and magnetic field
(Figure 2). We will describe representative examples of each
stimulus signal, focused on the latest examples. The
opportunities and challenges associated with clinical translations
will also be discussed.
2. COMPRESSIVE/TENSILE FORCE-TRIGGERED DRUG
DELIVERY
Compressive or tensile force-responsive DDS are mostly based
on stretchable materials, such as hydrogels and elastomers.68,77,78
Many formulations and devices, including nanoparticles and
microgel depots, have been exploited to be hybridized into a
flexible substrate to achieve on-demand release in response to
mechanical stimuli. Typical mechanisms for releasing entrapped
agents from systems are based on either physical deformation of
carriers or chemical changes of materials, such as breakage of
chemical bonds.
2.1. Deformation
Thermosensitive hydrogels have been extensively utilized for
spatiotemporal-controlled drug delivery.15 However, an external
heat source is usually required to activate the release. Pioletti and
co-workers79 attempted to employ the dissipative properties of
hydrogel as an internal heat source (Figure 3a). The hydrogel
matrix, which was formed with thermoresponsive nanoparticles,
produced self-heat after a cyclic mechanical loading for 5 min,
causing a temperature increase from 36 to 37 °C (Figure 3b).
The temperature increase led to shrinkage of the nanoparticles,
followed by contents release after 5−8 min (Figure 3c). This
hybrid hydrogel with high dissipation holds promise in the
delivery of growth factors by mechanical activation. Mooney and
Figure 3. Mechanically triggered drug release from thermoresponsive self-heating hydrogel. (a) Illustration of drug release from thermoresponsive
nanoparticle-loaded hydrogel with dissipation as an internal heat source. Thermoresponsive nanoparticles (blue dots) and drug (red dots) are loaded
inside the hydrogel (gray). (b) Temperature changes after cyclic compressive load. (Top) Temperature increases to 37 °C after 5 min loading from
initial temperature (36 °C). (Bottom) Temperature increases from initial temperature (34 °C) to 34.7 °C after 5 min loading. (c) (Top) Temporal-
controlled release of xylene cyanol FF triggered by dissipation properties of the hydrogel. (Bottom) Effect of nanoparticles on xylene cyanol FF release
during mechanical loading. Reprinted with permission from ref 79. Copyright 2014 Elsevier.
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co-workers80 developed a controlled delivery system based on
synthetic extracellular matrices (ECMs). The natural ECMs of
tissues, as depots of growth factors, are responsive to many
physiological signals and can correspondingly release factors to
surrounding cells. To mimic the behavior of natural ECMs, they
designed a hydrogel with reversible binding to drugs. The
reversible chemical binding was aimed at overcoming the limited
sensing period, since physically loaded hydrogel usually cannot
respond to compression after several release cycles due to rapid
depletion of drugs from the hydrogel.81 In this situation,
unbound vascular endothelial growth factor (VEGF) was
released upon each compression. However, with re-equilibration
of bound VEGF turning into unbound VEGF, the hydrogel could
continuously control the release of VEGF via compressive force.
Chemically cross-linked hydrogels integrated with mechano-
sensitive block copolymer micelles (BCMs) were reported to
have the capability to modulate drug release by mechanical force.
Jia and co-workers82 applied drug-loaded BCMs with reactive
handles as the microscopic cross-linkers instead of traditional
molecular cross-linkers for poly(acrylamide) (PAAm)-based
networks (Figure 4a). The restricted BCMs provided the
mechanoresponsive elements for BCM-PAAm gels, and the
force-induced deformation of BCMs led to drug release upon
strain application. At a strain of 200%, the BCMs presented a
more elongated appearance with an average dimension ratio of
1.53 ± 0.23 (Figure 4b). Furthermore, the BCMs returned to
their original morphology after removal of the external force due
to reversible structural deformation. Strain-dependent shape
alternation could effectively control the drug release rate from
the BCM-cross-linked gel (Figure 4c). The same group also
prepared hyaluronic acid (HA) gels covalently embedded with
dexamethasone (DEX)-loaded BCMs to control inflammation
within mechanically stressed tissues.83 The HA gels markedly
reduced the initial burst release and allowed sustained release in a
stress-dependent manner, which offers an alternative strategy to
take advantage of mechanical stress to promote tissue repair
during the wound-healing process.
Jeong and co-workers84 developed a strain-controlled system
that released molecules from an array of stretchable micro-
capsules based on a poly(dimethylsiloxane) (PDMS) elastomer
substrate using a hydrogel pattern fabrication technique (Figure
5a). The mechanical strain applied on the substrate led to
deformation of the polystyrene (PS) microcapsules (Figure 5b),
followed by pumped-out preload molecules. A strain of 2.5% on
the substrate reduced the microcapsule volume by 17%, while a
higher strain of 7.5% decreased the volume by 98%. The dosage
of released molecules was highly dependent on the degree of
strain (Figure 5c). The deformed PS capsules could return to
their initial shape and volume upon release from stretching,
which favored repeatable drug diffusion from the patch (Figure
5d).
In another example, Di et al.85 recently exploited a
multipurpose wearable elastomer that could mechanically
promote release of therapeutics to achieve “elastic drug delivery”
(Figure 6). The stretchable elastomer was integrated with
microgel depots that contained drug-loaded nanoparticles. The
drugs could be temporarily stored in the microdepots. When
stretching was applied, the drug could continuously diffuse out
due to deformation of the microgels, which was attributed to the
enlarged surface area for diffusion and Poisson’s ratio-induced
compression toward the microdepots. Therefore, an on-demand
drug delivery can be realized by convenient daily body motion.
Figure 4. Mechanoresponsive hydrogels based on block copolymer micelles (BCMs). (a) Synthesis of BCM-PAAm hydrogels. (b) Cross-sectional
transmission electron microscopie (TEM) images and schematics of unstretched, stretched, and recovered BCM-PAAm gels. (c) Effects of (i) periodic
stretching forces on (ii) release rate and (iii) cumulative release of pyrene from BMC-PAAm gels. Reprinted with permission from ref 82. Copyright
2012 Royal Society of Chemistry.
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On the other hand, pulsating release can be achieved through
intentional administration, which allows patients to control the
release timing and dose of drug on their own. Furthermore, when
combined with microneedle arrays, this device could be utilized
to regulate blood glucose levels (BGLs) by on-demand
transcutaneous insulin delivery for type 1 diabetic mice. After
several cycles of stretching and releasing, the BGLs of mice
quickly reduced to a normoglycemic level within half an hour.
Meanwhile, pulsating regulation of BGLs was observed when
strain was applied at 4 h intervals. With this technology, diabetic
patients can easily maintain BGLs via simple joint movement
instead of traditional, painful insulin injection. Kim et al.86 also
designed a stretchable reservoir-based patch-type system for
smart control of drug delivery. The liquid drop-based reservoir
loaded in a PDMS elastomer underwent a decrease in volume
and subsequently released the drug when the substrate was
deformed by external strains. Furthermore, the empty rubber
reservoir was readily refilled with a microsyringe to achieve long-
term release.
Besides volume change, crack propagation generated by an
applied strain can also be utilized to trigger drug release. On the
basis of this concept, Grinstaff and co-workers87 reported a
superhydrophobic polymer composite for a stretch-triggered
DDS (Figure 7). In their device, the drug-loaded hydrophilic
mesh core was encased by two superhydrophobic coatings with
different mechanical properties. This mismatch led tomechanical
failure of the coatings under applied tension, and the resulting
crack propagation allowed the cargo to diffuse from the mesh
core. The localized ex vivo study of this stretch-responsive device
incorporated with a metal esophageal stent indicated that the
model drug could be released to the esophageal epithelial mucosa
layer from the expanded system.
Lavalle and co-workers88 also developed a multilayer film with
a mechanotransductive surface for reversible biocatalysis
activation. The multilayer film, made by a layer-by-layer (LbL)
method, consisted of a poly(L-lysine)/hyaluronic acid (PLL/
HA) film as a reservoir, which was loaded with alkaline
phosphatase (ALP) enzymes and capped with a poly-
(diallyldimethylammonium)/poly(styrenesulfonate) (PDAD-
MA/PSS) film as a barrier (Figure 8a). ALP, a hydrolase
enzyme, can dephosphorylate fluorescein diphosphate (FDP).
Upon stretching, the loaded ALP was exposed through the
barrier; then the biocatalysis was switched on and the progress
was shown in confocal fluorescent images (Figure 8b). Besides
triggering of biocatalysis via stretching, biocatalytic activity can
also be controlled by the thickness of the barrier film. With
relatively thicker barrier layers, fewer enzymes could be brought
to the substrates, resulting in a lower jump of fluorescence
(Figure 8c). Reversible stretch-triggered biocatalytic activation
was achieved in this LbL system. The same group further applied
similar biodegradable polyelectrolyte multilayers as a mechanor-
esponsive drug delivery platform.89−91 Paclitaxel was embedded
in the PLL/HA reservoir, capped with a poly(allylamine
hydrochloride)/poly(styrenesulfonate) (PAH/PSS) film as the
barrier. When immerged in trypsin solution, PLL inside the
reservoir was cleaved by trypsin once the PAH/PSS barrier was
opened by mechanical stretch. Therefore, the entrapped
Figure 5. (a) Schematic of preparation of arrayed microcapsules. (b) Changes in the dimensions of microcapsules observed by AFM images and cross-
section analysis: (i) before and (ii) after stretching. (c) Release behavior of (1) FITC-labeled dextran and (2) rhodamine B under different strains. (d)
Amount of rhodamine B released upon stretching after consecutive stretching and release events. Repinted with permission from ref 84. Copyright 2011
Wiley−VCH.
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paclitaxel was released from films as a result of biodegradation of
PLL/HA film in a stretch-controlled manner.
2.2. Mechanochemical Change
Mechanical force-induced chemical changes, including isomer-
ization, ring opening, chain scission, and other intermolecular
interactions can be useful in many biomedical applications, such
as self-healing, actuators and sensors, as well as DDS.67,68,78,92,93
Larsen and Boydston94 developed a mechanochemical-
sensitive elastomeric matrix embedded with mechanosphores
that had the capacity to load and release a furan derivative in
response to physical stress (Figure 9). The mechanophore with
an oxanorbornadiene group could be activated upon mechanical
stress. During this process, the applied stress directed the bond-
bending motion to further break bonds orthogonal from the
polymer backbone through retro [4 + 2] cycloaddition.
Consequently, with the flex-activated mechanophore inside the
cross-linked polyurethane network, the elastomer performed in a
force-activated manner. It could release small molecules over
multiple load cycles, which showed the potential of sequential
release in an on-demand feature. In another work, Izawa et al.95
reported a β-cyclodextrin (CyD) cross-linked alginate gel for
patient-controlled drug delivery via mechanical regulation of
host−guest interactions. In this study, the CyD moiety was
chosen as the mechanophore, which underwent deformation
upon compression and released the entrapped ondansetron
(ODN) due to the variation in inclusion capability of CyD.
The previously explored examples indicate the potential of
compressive or tensile force-responsive materials for controlled
drug release by simple bodily motion during daily life. The tensile
and compressive forces can be conveniently obtained without
additional external instruments. However, more robust dosage
control is required for further clinical applications.
3. SHEAR FORCE-INDUCED DRUG DELIVERY
Hemodynamic shear force, known as a crucial parameter of
vascular pathophysiology, is a frictional drag force imposed by
blood flow.96 Obstruction of normal blood flow results in a
dramatic increase in shear stress (1−2 orders in magnitude),
which poses a threat to millions of people around the world for
stroke and atherosclerosis.97 Specifically, shear stress in normal
vessels generally remains below ∼70 dyn/cm2, while a 95%
Figure 6. Stretch-responsive wearable elastomer films for controlled drug delivery. (a) Schematic of tensile strain-activated drug release. (b)
Photography and SEM image of prepared microneedle (MN) patch, and its application on streptozotocin (STZ)-induced type 1 diabetes mice. (c)
Elastomer film for anti-cancer, anti-inflammatory, and diabetes therapy. (Top)NormalizedHeLa tumor spheroid sizes andmorphologies (insets) before
treatment, without treatment, and treated with media fromDOX-formulated devices after 10 cycles of stretching or without stretching after 3 days. Scale
bars: 100 μm. (Middle) Antibacterial assay using solutions containing released ciprofloxacin after 100, 400, and 1000 cycles of finger flexions. Passive
released ciprofloxacin was included as a control. (Bottom) BGL change of diabetic mice after (1) wearing devices with 10 cycles of 50% stretching with
an interval of 4 h by hand (red line), (2) wearing devices without stretching (passive) (black line), (3) being subcutaneously injected with insulin
solution with the same dose as applied into the microdepots used in (1) and (2) (blue line), and (4) being subcutaneously injected with phosphate-
buffered saline (PBS) solution only (green line) (n = 4). Reprinted with permission from ref 85. Copyright 2015 American Chemical Society.
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constricted stenotic or thrombosed artery possesses stress above
1000 dyn/cm2.98−100
Although there are a multitude of stimuli-responsive DDS,
covering redox, temperature, and external signals,101,102 as well as
many formulations such as liposomes and micelles,103−106 it still
remains challenging to construct on-demand drug delivery for
cardiovascular diseases.107,108 Given the distinguishable shear
force in vascular fluid, shear-sensitive DDS may be an emerging
outlet for noninvasive therapy of vascular-related diseases.109−111
In this section, shear force-promoted DDS will be reviewed that
are based on either disaggregation or deformation of drug
carriers.
3.1. Disaggregation
Platelets, components in blood with a long circulation time,
aggregate and coagulate to cease bleeding during blood vessel
injuries.112 Once shear force increases, platelets sense this change
and respond by activating and adhering to the vascular wall at
these narrowed sites.99 Inspired by the physiological response of
platelets, Ingber and co-workers72 designed microscale aggre-
gates of nanoparticles to mimic platelets, which could remain
intact in normal physiological flow. However, they broke up into
individual nanocomponents once activated by high shear force
and then adhered and accumulated at stenotic regions. The
disaggregated nanoparticles were exposed to much lower drag
force compared to the microscale aggregates, allowing for
localization and accumulation on endothelial cells (Figure 10).
On the other hand, an increase in total exposed surface area of the
particles further facilitated release of the payload that was
immobilized on the nanoparticle surface. In vivo experiments
implied that the microaggregates coated with tissue plasminogen
activator (tPA) rapidly dissolved the clot in 5 min in a mesenteric
injury model (Figure 10c) and remarkably enhanced the survival
rate up to 80% in another fatal mouse pulmonary embolism
model.
Most recently, Chen et al.113 took advantage of shear force as a
weapon for antithrombus therapy (Figure 11a). Heparin, an
anticoagulant drug, was formed into nanoparticles via hybrid-
ization with polypeptide PLL. These positively charged heparin
nanoparticles (cNPs) were then absorbed to negatively charged
red blood cells (RBCs) via electrostatic attraction for long-term
circulation. The large size of RBCs prevented the cNPs from
extravascular diffusion and benefited the drug’s intravascular
release. On thrombus sites, the shear stress significantly increased
due to narrowing of the blood vessels, which led to site-specific
release of cNPs from RBCs. Scanning electron microscopic
(SEM) images indicated that, with higher shear stress (10 Pa vs 1
Pa), more desorption of cNPs from RBCs was observed after 24
and 48 h (Figure 11b). With the help of RBCs as the drug
delivery vehicle, the drug could be delivered to target
destinations with a prolonged circulation time.
3.2. Deformation
Another strategy is to utilize shear force-induced deformation of
carriers to release therapeutics. Budtova and co-workers114 first
presented a shear-induced controlled release from hydrogels and
microcapsules. They observed the solvent release from either
hydrogels or microcapsules upon exposure to silicon oil flow, and
over 30% deformation was generated by the flow shear stress.
Their results showed that there was a threshold for shear stress to
produce deformation. Once above the critical point, the particles
would break up and release the cargo inside, which indicates that
shear force-induced release is feasible.115 Furthermore, they
designed a microgel that could release contained fullerene by the
function of shear and swelling.116 Holme et al.71 demonstrated
that lenticular-shaped vesicles could sense elevated shear stress
(Figure 12a). The lenticular liposome was prepared from the
artificial phospholipid Pad-PC-Pad through an extrusion method
(Figure 12b). The two amide bonds of lipid can increase the
stability of the polar region on the membrane via hydrogen
Figure 7. Stretch-triggered drug delivery based on superhydrophobic polymer composites. (a) Schematic of preparation and mechanism of tension-
responsive system. The electrosprayed barrier coating (yellow) prevents unwanted drug release from the core (green). (b) SEM image of device cross-
section and advancing water contact angles for electrosprayed hydrophobic (top, PCL) and superhydrophobic (bottom, PCL:PGC-C18 1:1) coatings.
(c) Contrast-enhanced microcomputed tomography (mCT) images observed before and after tensile strain application and sequential images during
stretching along the x-axis. (d) Release profiles of model hydrophilic dye from the tension-responsive system via crack propagation. Reprinted with
permission from ref 87. Copyright 2016 Wiley−VCH.
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bonds. The Pad-PC-Pad substitution at 1- and 3-positions of the
original glycerol backbone was attributed to directional hydro-
gen-bond formation in the polar region (Figure 12d). The
lenticular shape of the Pad-PC-Pad liposomes led to preferential
breaking points along the equator upon application of shear force
and subsequent transient leakage of trapped cargos. With a 100%
Pad-PC-Pad component, the vesicles were more stable and
showed specific release in the high-shear-stress constricted-artery
model (Figure 12c). The results from an in vitro cardiovascular
model showed that almost 30% more dye was released from
lenticular vesicles when flowing through a constricted tube
compared with a patent tube. Further in vivo studies need to be
conducted. If successful, this observation might be applied in
vascular-targeted treatment. Mitragotri and co-workers117,118
also designed biomimetic platelets for targeted drug delivery to
vascular injuries. Platelet-like nanoparticles (PLN) were
synthesized by the LbL approach (Figure 13a). Specifically,
complementary layers of poly(allylamine hydrochloride) (PAH)
and bovine serum albumin (BSA) were coated on a template
particle, which is a PS nanoparticle.118 After removal of the
template core, the PAH/BSA multlilayer shell collapsed into a
flexible particle and could change its shape in response to shear
force (Figure 13b). It was found that small particles were more
likely to adhere and aggregate under high-velocity flow in a
microfluidmodel, which was due to the weaker shear detachment
force experienced by relatively small particles. PLNs with 200 nm
diameter covered more surface area of the fluid channel than
either spherical or disc-like particles of the same size, which
mainly contributed to their flexible shape under shear. Moreover,
with targeted peptide modification on their surfaces, the PLNs
exhibited significantly higher adhesion to injury sites under shear
stress in an in vitro wound model (Figure 13c). And these
functional peptides, which were collagen- and von Willebrand
factor-binding peptides (CBP and VBP) and fibrinogen-mimetic
peptide (FMP), could simultaneously bind to activated natural
platelets and injured endothelial sites to amplify platelet
aggregation for hemostasis. They showed that the peptide-
Figure 8. Stretch-activated biodegradation of LbL reservoir films. (a) Mechanism of stretch-activated biocatalysis: (i) Catalysis is off when the film is
unstretched. (ii) After stretching, enzymes are exposed and the biocatalysis turns on. (iii) Released phosphate ions inhibit enzymes in a feedback
manner. (iv) After rinsing, the enzymes are reactivated for further catalysis. (b) Confocal microscope section (x,z) images of silicone sheets with
multilayer films loaded with ALP enzymes. (c) Biocatalytic activity of reservoir/barrier films triggered by stretching for three different barrier thicknesses
(m = number of bilayers). α = 0% (unstretched state) and α = 110% (stretched state). Reprinted with permission from ref 88. Copyright 2009 Nature
Publishing Group.
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modified PLNs could reduce the tail bleeding time of mice by
∼65% in a tail amputation test (Figure 13d).
Besides the shear-induced deformation of drug carriers, shear
force can also be employed to temporarily disrupt cell
membranes for intracellular drug delivery.119 The Langer and
Jensen laboratories119 designed a microfluidic device that can
deliver a range of materials, including macromolecules, into cells
(Figure 14a). A relatively narrow channel (30−80% smaller than
cell diameter) was fabricated in the device to produce
compression and shear force. When cells, such as embryonic
stem cells and immune cells, passed through the constricted
channel, transient holes on the cell membrane were generated,
which further enabled the diffusion of surrounding cargos across
the membrane. Moreover, it demonstrated 10-fold enhanced
delivery efficiency of transcription factors compared to cell-
penetrating peptides (Figure 14b). Besides application in cell
reprogramming, this technique also enabled direct delivery of
quantum dots, carbon nanotubes, and proteins to cell cytosol for
probe-based sensing (Figure 14c). The diffusion delivery
mechanism was proved and characterized by monitoring the
delivery kinetics, which indicated 70−90% cargo delivery within
the first minute (Figure 14d). The membrane disruption-based
mechanism offers flexibility in delivery, since it does not rely on
exogenous materials or endocytotic pathways. Furthermore,
unlike current existing methods, the microfluidic device showed
no damage to either payloads or cells, and hence improved
biological activities. Such capabilities of the technique expand its
prospects in therapeutic applications, and a company (SQZ
Biotech) was established on the basis of this concept, aiming to
improve the CellSqueeze platform for efficient cell therapy.
Thereafter, relevant research on interactions between micro-
fluid and platelet mimetics or vesicles was conducted to promote
shear-responsive DDS.120−124 PEG [poly(ethylene glycol)]
coating, multilamellar shell, and surface charge all affect the
stability and uptake efficacy of carriers. The influence of platelet
endothelial cell adhesion molecules (PECAMs) on shear stress
differently regulated endothelial uptake of nanocarriers was also
evaluated.125,126 These targeting agents, including PECAMs and
glycoproteins, were adhered to nanocarriers for targeted
endothelial drug delivery.127,128
The research discussed above strengthens the feasibility of
shear force-induced drug delivery for cardiovascular disease
treatment. Shear force-sensitive drug carriers are able to achieve
spatial- and temporal-controlled release in a noninvasive manner.
However, their clinical application is still limited due to several
challenges such as short circulation time and safety issues.
4. ULTRASOUND-ACTIVATED DRUG DELIVERY
Ultrasound is a sound wave with frequencies above 20 kHz.129 It
can generate longitudinal force/pressure that induces mechanical
force or/and local heating in a noninvasive manner.130
Ultrasound has been widely used for therapeutic purposes
since the beginning of the 20th century, including tissue ablation,
kidney stone shattering, imaging, liposuction, and transdermal
drug delivery.131−135
Ultrasonic waves can map the location and promote drug
release from carriers by causing localized hyperthermia, acoustic
cavitation, or/and acoustic radiation forces as designed.130 The
acoustic force can change the permeability or absorption of
tissues and “push” the drug into the cells or across the tissue.
Furthermore, it can also change the chemical properties of
Figure 9. (a) Schematics of flex activation in an oxanorbornadiene-based mechanophore. The oxanorbornadiene group is released upon mechanical
stress as a result of breaking bonds orthogonal from the polymer backbone through retro[4 + 2] cycloaddition. (b) Synthesis of polyurethane networks.
Reprinted with permission from ref 94. Copyright 2014 American Chemical Society.
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materials. In 1989, Kost et al.136 reported that ultrasound could
facilitate the degradation process of polymer materials and
subsequently enhance the release of incorporated substances.
Afterward, drug-loaded microbubbles were illustrated to be
intentionally ruptured by ultrasound, which presented effective
spatiotemporal control of drug release with a nondestructive
feature.137 To date, a wide range of drug carriers, such as
liposomes, micelles, nanoparticles, and micromotors, have been
explored for ultrasound-triggered drug delivery.75,138−140
Ultrasound with frequency between 20 and 100 kHz is defined
as low-frequency ultrasound (LFUS), which is usually used to
induce sonophoresis and affect drug carriers such as lip-
osomes.132,141,142 LFUS was also applied to temporarily enhance
permeability of skin for transdermal drug delivery.143,144
Mitragotri et al.145,146 and others147 reported that large molecular
proteins, such as insulin (∼6 kDa) and erythropoietin (∼48
kDa), as well as other drugs can be transported across the skin
due to the disorganization of tissue induced by LFUS. Recently, it
was reported that LFUS could locally promote drug delivery in
gastrointestinal systems.148 In both mouse and pig models, it
showed treatment efficacy without significant safety issues.
High-frequency ultrasound (HFUS), which has a frequency
greater than 1 MHz, is used to trigger oscillations in
microbubbles.149 Additionally, it has been shown that the
acoustic pressure associated with cavitation derived from
ultrasound waves can induce carrier destruction, drug release,
and temporary increase in membrane permeability, thus
facilitating the cellular uptake of therapeutic agents.150−152
The following sections will mainly focus on nonthermally
activated drug delivery. Since microbubbles have been widely
discussed in a number of reviews,74,153−155 here we briefly
introduce the most recent progress.
4.1. Microbubbles
Microbubbles, which are gas-filled spheres dispersed in aqueous
medium with an average size between 1 and 8 μm, have been
widely employed in ultrasound imaging as ultrasound contrast
agents.74,156 The bubbles experience oscillations under a HFUS
field when driven by a frequency near resonance and even can
end up with a rupture.137,157 By decreasing the threshold for
cavitation, the collapse of drug-encapsulating microbubbles can
also be used in ultrasound-activated drug delivery (Figure 15).158
Furthermore, Dayton and co-workers159 discovered that micro-
bubbles serve as cavitation nuclei and can enhance ultrasound
energy deposition in cells and tissues, thus facilitating intra-
cellular drug transport by disruption of their membranes.160,161
Recently, numerous studies have been reported on the
application of microbubbles for drug or gene delivery,
particularly in brain tumor in situ/targeted treatment and
Figure 10. Shear force-triggered system for targeted delivery to obstructed blood vessels. (a) Preparation of platelets mimicking microscale aggregates.
(b) Schematic of hemodynamic shear targeting to stenotic vessels by use of platelet mimetics. (c) Change of clot size after injection of tPA-coated shear-
activated nanotherapeutics (SA-NTs) (left) compared to PBS treatment (right) in a partially occluded mesenteric artery. Scale bar, 100 mm. Reprinted
with permission from ref 72. Copyright 2012 American Association for the Advancement of Science.
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cardiovascular therapy.73,155,159,162 Effective drug delivery to
brain is limited due to the blood−brain barrier (BBB) and the
blood−tumor barrier (BTB).163−165 Focused ultrasound has
shown to be capable of transiently opening the BBB in the
presence of microbubbles.166−168 To date, a large number of
therapeutic agents have overcome the barrier and have been
delivered into the brain or a brain tumor.169,170 Yeh and co-
workers171 designed superparamagnetic iron oxide nanoparticles
conjugating with doxorubicin-loaded microbubbles (DOX-
SPIO-MBs) for imaging-guided drug delivery to brain tumors
(Figure 16). It was found that the superparamagnetic/acoustic
properties of DOX-SPIO-MBs were suitable for imaging.
Ultrasound concurrently induced BBB opening and promoted
drug delivery, which enhanced the brain tumor treatment effect.
They further modified targeting ligands on microbubbles to
facilitate directing chemotherapeutic agents to regions of tumor
vasculature.172 Kovacs et al.173 also demonstrated that micro-
bubbles might serve as an effective method for glioblastoma
multiforme (GBM) treatment after investigating ultrasonic
microbubble therapy in two GBM mouse models.
Researchers have also attempted to apply ultrasound-triggered
microbubbles in ovarian cancer and prostate cancer treatment, as
well as in lymph nodes and in other tumor therapy.174−176
Attributed to the spatial and temporal control of drug delivery
that is feasible by ultrasound, microbubbles can aid in a variety of
diseases therapy besides cancer. For example, drugs could be
delivered to the inner ear through the round window membrane,
resulting in 3.5−38 times higher delivery by ultrasound than that
by spontaneous diffusion.177 In addition, genetic drugs could be
specifically delivered to the skeletal muscles of mice.178
Besides drugs encapsulated in microbubbles, some researchers
developed a new formulation with drug-loaded nanocarriers
coated on microbubbles. As reported in the literature, nano-
particles have been linked to microbubbles through avidin−
biotin interaction; however, the washing steps may influence the
stability of the microbubbles.179−181 On the other hand, self-
Figure 11. Shear force-triggered system for antithrombus therapy. (a)
Schematic of preparation of cNPs adsorbed to red blood cells (RBC-
cNPs) and mechanism of shear-induced release of cNPs. (b) SEM
images showing shear force-triggered desorption of heparin/polypep-
tide hybrid nanoparticles cross-linked with disulfide bonds (cNPs) from
red blood cells (RBCs) as a function of time. (A) RBC-adsorbed cNPs
(RBC-cNPs) under static conditions. (B, C) RBC-cNPs under 10 Pa
shear-stress treatment for (B) 24 and (C) 48 h. (D, E) RBC-cNPs under
1 Pa shear-stress treatment for (D) 24 and (E) 48 h. Scale bar = 4 μm.
Reprinted with permission from ref 113. Copyright 2016 Wiley−VCH.
Figure 12. Shear force-responsive lenticular vesicles for targeted drug delivery. (a) Mechanism of shear force-activated drug delivery. (b) Cryo-TEM of
Pad-PC-Pad vesicles. (c) Release behavior of L-α-phosphatidylcholine (eggPC) vesicles with different Pad-PC-Pad at 37 °C before (untreated) and after
one pass only through either healthy or constricted arterial models. (d) Chemical structure of phospholipid Pad-PC-Pad. Reprinted with permission
from ref 71. Copyright 2012 Nature Publishing Group.
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assembled microbubbles loaded with liposome have recently
shown their potential as a promising drug delivery carrier to
cancer tissues, which could eliminate cancer cells with a very low
dose of therapeutics (0.5 μg/mL DOX) as demonstrated by De
Smedt and co-workers.182 Drug-loaded liposomes, formed with
functionalized (SPDP-)PEG-lipids, were conjugated to the
microbubbles containing the hydrophobic perfluorobutane
(C4F10) gas through thiol−maleimide linkages. Approximately
600−1300 liposomes were bound per single microbubble, and
the size of the microbubbles increased from 3.6 to 4.0 μm after
conjugation with liposomes (diameter around 200 nm),
indicating the formation of a single liposome layer coated on
the surface of the microbubbles. The same group183 designed N-
cadherin-targeted liposome-loaded microbubbles for circulating
tumor cell (CTC)-specific drug delivery (Figure 17). Their
results confirmed that the targeted antibodies specifically
adhered to the target cells and that focused ultrasound helped
transport small molecules (propidium iodide) into the cells.
Sanders and co-workers184 further proved that liposome-
decorated microbubbles could enhance ultrasound-mediated
drug delivery in vivo. They chose indocyanine green (ICG) as a
model drug for intravenous injection inmice andmonitored local
ICG deposition post-ultrasonic therapy via fluorescence imaging.
4.2. Liposomes
The relatively large size of microbubbles results in a shorter
retention time compared to nanocarriers. The inevitable
retention in the lungs also restricts the use of microbubbles in
cardiovascular targets and tumor endothelia. Hence, acoustically
activated liposomes, sometimes called nanobubbles, have
become more prominent in ultrasonic drug delivery.132,185,186
This kind of ultrasound-responsive liposomes (echogenic
liposomes), which are typically formed with a gas core covered
with a lipid monolayer, were initially studied for ultrasound
imaging as contrast agents.129,187,188 Lin and Thomas189 found
that LFUS could control the release of the payload from drug-
encapsulating echogenic liposomes with nonthermal effects.
Under the appropriate ultrasound frequency, echogenic lip-
osomes rapidly grew, oscillated, collapsed, and spewed payload
by cavitation. Several factors like wave frequency, membrane
constituents, encapsulated gas or drug, presented media, and size
and shell thickness of liposomes can affect the stability of
liposomes and liposomal drug release.190−193
Liposomes containing monolayer lipid-covered bubbles are
known as bubble liposomes (BLs).194−196 Aramaki and co-
workers197 employed BLs along with ultrasound exposure to
directly deliver plasmid DNA (pDNA) to skeletal muscles by
local injection for peripheral artery disease treatment. PEG-
modified BLs with perfluoropropane gas were easily fabricated
through a reverse-phase evaporation method. It was found that
high gene transfection efficiency was achieved in the muscle
administrated with BLs and ultrasound in a hind-limb ischemia
mice model, as well as an increase in capillary density and blood
flow. Furthermore, in order to deliver genes to deeper tissues,
novel BLs were explored for systemic injection, by use of a
Figure 13. (a) Synthesis of platelet-like nanoparticles (PLNs). (b) SEM images of (i) sacrificial 200 nm spherical polystyrene (PS) templates, (ii) PAH/
BSA-coated PS templates, and (iii) final PLNs. Scale bars = 200 nm. (c) In vitro binding of PLNs with and without functional peptides to targeting
surface and nontargeting BSA surface (control) under shear stress. (d) Bleeding time was reduced after treatment of PLNs in a tail amputation model in
mice. Reprinted with permission from ref 118. Copyright 2014 American Chemical Society.
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cationic lipid (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethy-
lammonium, DOTAP) to intensify the colocalization of pDNA
and BLs via electrostatic attraction (Figure 18).198 Results
showed that improved design of BLs brought about higher
loading efficiency of pDNA through its interaction with DOTAP
and prolonged circulation time by adjusting the ratio of short-
and long-length PEG (PEG750/PEG2000) molecules on the
surface. Additionally, Pitt and co-workers199 prepared emulsion-
containing liposomes (eLiposomes) for drug delivery, with a size
of 200−400 nm. They demonstrated that ultrasound could cause
acoustic droplet vaporization (ADV) of the contrast agent, thus
breaking the liposomal membrane. After DOX loading,
eLiposomes exhibited an improved therapeutic response in
vitro. Some other eLiposomes were also reported in several
studies.200,201
Indeed, LFUS can also induce drug release from conventional
liposomes without contrast agents. By forming a gas bubble core
in the hydrophobic interval between lipid bilayers, which would
grow until it permeates the liposome membrane, ultrasound can
finally produce transient pores for drug diffusion. Cisplatin and
DOX haven been widely delivered from liposomes triggered by
ultrasound for cancer therapy.132 DOX-loaded liposomes
modified with targeting ligands were applied to brain tumors
with pulsed ultrasound assistance and showed improved
anticancer effects.202 Fossheim and co-workers203 developed
sonosensitive liposomes by doping nonbilayer lipid (distear-
oylphosphatidylethanolamine, DSPE) on the surface of lip-
osomes. DOX-containing liposomes composed of dioleoylphos-
phatidylethanolamine (DOPE) showed even higher sonosensi-
tivity, since DOPE tended to form amore pronounced hexagonal
Figure 14. Shear stress-reponsive intracellular drug delivery. (a) Rapid deformation of a cell due to transient membrane holes, when it passes through a
microfluidic constriction. (b) Western blot analysis of cellular uptake of c-Myc, Klf4, Oct4, and Sox2 by NuFF cells by cell-penetrating peptides versus a
microfluidic device, which showed higher delivery efficiency by microfluidic constriction. (c) Delivery efficiency of carbon nanotubes in treated cells
(left) vs endocytosis (right). Scale bars: 2 μm. (d) Live-cell delivery efficiency of different designed devices. Reprinted with permission from ref 119.
Copyright 2013 U.S. National Academy of Sciences.
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structure due to its unsaturated acyl chains.204 Thus, upon
exposure to ultrasound, the phase transition of DOPE induced
membrane perturbations, followed by drug release from
liposomes.
4.3. Nanoparticles
Polymeric micelles typically assembled by amphiphilic block
polymers have been ubiquitously used in drug delivery for
decades.13 Micelles made from thermosensitive polymers can be
disrupted by ultrasound; therefore, ultrasound-assisted micellar
drug delivery has been recently studied.205 Furthermore,
mechanical action caused by pulsed ultrasound can also trigger
drug release from micelles. Many micelle-based DDS incorpo-
rated with local sonication were reported as efficient tumor-
selective treatments.206−208 Xia and co-workers209 studied
ultrasound-responsive behavior of PLA-b-PEG [poly(lactic
acid)-b-poly(ethylene glycol)] copolymer micelles under high-
intensity focused ultrasound (HIFU) (Figure 19). Results
revealed that generated transient cavitation led to the
degradation of PLA-b-PEG under HIFU at the ultrasound focal
spot. They also invented a dual-responsive micelle with a
disulfide bond that could be broken under reductive con-
ditions.210 Thus, this micelle can be remotely controlled by
HIFU and simultaneously stimulated by an intracellular
bioreductive environment.
Several publications have also reported that ultrasound can
promote gene delivery from nanoparticles. Gene transfection was
enhanced when complexes of genes and cationic lipids or
polymers were treated by ultrasound.211−213 Wang et al.214
investigated various acoustic parameters to facilitate the delivery
of microRNA from PLGA−PEG [poly(lactic-co-glycolic acid)−
poly(ethylene glycol)] nanoparticles to the tumor site in
cooperation with microbubbles. Evidence showed a 7.9-fold
increase in delivery efficiency compared to treatment without
ultrasound. Concurrent application of ultrasound and sodium
lauryl sulfate could also enhance the passive transdermal delivery
efficacy of nanoparticles.215 In addition, mesoporous silica
nanoparticles (MSNs), as ultrasound contrast agents, were also
reported to be useful for ultrasonic drug delivery.216 Results
demonstrated that the target antibody (herceptin) functionalized
MSNs could potentially be used for ultrasound activated imaging
and tumor-specific treatment for breast cancer.
Figure 15. Illustration of application of drug-loaded microbubbles in drug delivery systems. Microbubbles can prevent drugs from degradation in the
bloodstream and avoid uptake in unwanted areas. At the target site, the drug can be released and penetrate cell membranes by application of ultrasound.
Reprinted with permission from ref 158. Copyright 2012 Elsevier.
Figure 16. Schematic of controlled release of DOX-SPIO-MBs into brain tissues triggered by ultrasound and enhanced SPIO deposition by external
magnet targeting. Reprinted with permission from ref 171. Copyright 2013 Elsevier.
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It has also been shown that nanodroplets (NDs) formed with
lipid-stabilized low-boiling perfluorocarbon could release their
cargo via interaction with ADV caused by ultrasound. Acoustic
droplets were reported for ultrasound-mediated targeted drug
delivery.217−219 Yeh and co-workers220 prepared folate-deco-
rated NDs (FA-CPT-NDs) entrapping camptothecin (CTP) as
an acoustic drug carrier for targeted tumor theranostics in a
mouse xenograft model. The FA-CTP-NDs underwent a
transition shift from liquid to gas upon ADV, followed by release
of CTP and apoptosis of the targeted cancer cells. This
formulation exhibited enhanced chemical and mechanical
antitumor effects. Superparamagnetic iron oxide could also be
embedded into nanodroplets to assist inmagnetic control of drug
deposition.221
Emulsion is known as a two-phase mixture with a dispersed
phase surrounded by a continuous phase. Hydrocarbon or
fluorocarbon liquids are two common dispersed phases that can
carry hydrophobic agents.162,222 Perfluorocarbon nanoemulsions
stabilized by copolymers could deliver lipophilic therapeutics to
solid tumors.223 Ultrasound would trigger ADV and reversibly
transport droplets to gas in PFCE (perfluoro-15-crown-5-ether)
nanoemulsions. Desired therapeutic effects were observed in
both breast and pancreatic cancer animal models with ultrasonic
delivery of paclitaxel loaded in PFCE nanoemulsions. The
biodistribution of nanoemulsions could be simultaneously
monitored via ultrasonography. Stone and co-workers224
developed an ultrasound-sensitive gas-in-oil-in-water-in-oil triple
emulsion through a microfluidic method. The triple emulsions
were stable in the atmosphere; thus it was possible to reinforce
the emulsions through polymerization by UV light outside the
device and turn it into gas-in-liquid-in-solid compound particles.
When ultrasound was applied, the gas core induced breakage of
emulsions and released the encapsulated contents.
Figure 17. Schematic depictions of (a) a targeted liposome-loaded
microbubble and (b) intercellular uptake into circulating tumor cells.
Adapted with permission from ref 183. Copyright 2013 Wiley−VCH.
Figure 18. Schematic presentation of systemic gene delivery systems using bubble liposomes (BLs) entrapping ultrasound contrast gas. This
combination of BLs and ultrasound exposure provides an effective way for the delivery of plasmid DNA (pDNA) into skeletal muscles. Reprinted with
permission from ref 198. Copyright 2012 American Chemical Society.
Figure 19. Scheme of HIFU and redox dual-responsive process of PEG-
S-S-PLA micelle. Upon HIFU irradiation or glutathione treatment,
degradation of the PEG-S-S-PLA chain and disruption of micelles can
trigger drug release. Reprinted with permission from ref 210. Copyright
2010 Royal Society of Chemistry.
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4.4. Micro/nanomotors
Micro/nanomotors are a class of miniaturized synthetic
machines, which are capable of converting chemical or external
energy to mechanical motion.225 Over the past decade,
numerous artificial micro/nanomotors based on diverse
propulsion mechanisms have been developed in a wide variety
of medical applications ranging from bioanalytics to drug
delivery.226−229 However, previously reported synthetic motors
were mostly propelled by chemically catalyzed gradients or by
ejecting bubbles that usually contained toxic ingredients like
H2O2.
230,231
Mallouk and co-workers232 utilized continuous or pulsed
ultrasound for the propulsion of metallic micromotors. As
ultrasound-powered micromotors showed considerable promise
in penetrating into deep tissues, Mallouk and co-workers233
further employed rod-shaped nanomotors into HeLa cells. They
demonstrated that the desired intercellular uptake of gold
nanorods was achieved with the assistance of ultrasound and
without any chemical fuel, and insignificant toxicity was detected
toward cells. Intrigued by their work, Wang and co-workers234
developed ultrasound-poweredmicrobullets that could penetrate
and deform cellular tissues and deliver drugs to diseased
destinations (Figure 20). These tubular microbullets loaded
with ultrasound contrast agent (perfluorocarbons, PFCs) inside
the conical-shaped microtubes could produce sufficient force to
contribute to the ADV of PFCs. Consequently, a “bulletlike”
velocity of over 6 ms−1, approximately 100 times faster than
common micromotors, was assessed, offering PFC-loaded
micromotors as a possible platform to deliver drugs through
the tissue barrier. The same group developed a multifunctional
nanowire motor consisting of three metallic segments (Au−Ni−
Au) that was propelled by ultrasound and guided by magnet-
ism.235 The pH-sensitive eletropolymerized polypyrrole−poly-
(styrenesulfonate) (PPy−PSS) was linked to the Au−Ni−Au
nanowire, serving as a drug carrier for a model drug, brilliant
green (BG). Similarly, they used ultrasound to drive nanoporous
Au nanowires with the drug inside toward the cancer tissue and
triggered the release by near-infrared light (NIR).236 Wu et al.237
fabricated polymer-based multilayer tubular nanorockets via LbL
assembly assisted with a nanoporous template, which were
verified to efficiently transport drugs into cancer cells. Poly-
(diallyldimethylammonium chloride)-stabilized platinum nano-
paticles were incorporated into the inner layer (as framework of
the nanorockets), while DOX was loaded into the outer layer (as
container of the nanorockets). The self-propelling nanorockets
were shown to partially penetrate into the HeLa cells and release
DOX through ultrasound-mediated breaks of the outer layers.
Recently, Wang and co-workers238 further developed a kind of
micromotor based on natural particulates by inserting iron oxide
nanoparticles inside red blood cells to prolong circulation time
and improve biocompatibility.
4.5. Microcapsules
Van Hest and co-workers239 fabricated a series of hollow
biodegradable polymeric microcapsules and studied the
mechanical effects of PFO−PLLA [perfluorooctanol−poly(lactic
acid)] capsules with varied ratios of shell thickness to diameter
under different acoustic pressures. Thus, drug release from
PFO−PLLA capsules could be triggered independently in a
stepwise or selective fashion by control of mechanical index. In
another work, Wang et al.240 utilized alginate microcapsules as
drug carriers incorporated with pulsating ultrasound to deliver
diclofenac for anti-inflammatory purposes, obtaining a 30%
higher release rate in vivo.Möhwald and co-workers241 fabricated
polyelectrolyte microcapsules with ZnO nanoparticles embed-
ded in the shell, which resulted in considerably higher ultrasound
sensitivity. It was demonstrated that the shell thickness and
roughness is dependent on the number of ZnO nanoparticle
layers. Their different mechanical properties affected sensitivity
to ultrasonic treatment. This ZnO nanocomposite showed its
potential as a drug carrier with the possibility of opening with the
application of ultrasound.
Moreover, lasers can also generate focused ultrasound for
spatiotemporal control of drug delivery. Gu and co-workers242
demonstrated a laser-generated focused ultrasound (LGFU)-
triggered drug delivery device. Compared to the conventional
HIFU, LGFU can focus on a tight spot with a higher resolution
and reduce the heating effect on tissue. Different types of drugs,
such as DOX for anticancer treatment and ciprofloxacin for
antibacterial treatment, were encapsulated in PLGA nano-
particles. Then the PLGA nanoparticles were further loaded
into alginate microgels. Upon applying LGFU onto microgels, a
significant promoted drug release was observed at the focal point
due to the cavitation effect. They demonstrated that
spatiotemporally remote control of drug release could be
achieved in in vitro antitumor and antibacterial studies via
application of LGFU.
4.6. Injectable Depots
Recently, several injectable and ultrasound-responsive depot-
based DDS have also been developed for long-term admin-
istration. For example, Gu and co-workers243 reported a smart
nanonetwork that was able to regulate BGLs by ultrasound-
triggered insulin release (Figure 21a). The gel-like 3D nano-
scaffold was formed with alginate- and chitosan-coated PLGA
Figure 20. (a) Preparation of PFC-loaded microbullets. (b) Computer-
aided graphics and coresponding experimental images of PFH-loaded
microbullets (i) penetrating, (ii) cleaving, and (iii) expanding a tissue
following a pulsed ultrasound signal. Reprinted with permission from ref
234. Copyright 2012 Wiley−VCH.
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nanoparticles via electrostatic attraction. Insulin was loaded in
the nanoparticles, and the formed cohesive nanonetwork could
be subcutaneously injected through a universal syringe due to
reduced cohesive forces under high shear rate. The nanonetwork
could remain stably underneath the skin with tight adhesion of
oppositely charged nanoparticles. Once focused ultrasound was
applied, the nanonetwork was partially dissociated, and stored
insulin diffused out from the microchannels in the porous
scaffold (Figure 21b). In particular, they demonstrated that the
release rate could be controlled by tuning the parameters of
focused ultrasound such as input voltage, pulse duration, and
ultrasound administration time (Figure 21d). In vivo experi-
ments showed that the insulin-loaded nanonetwork helped
regulate BGLs of type 1 diabetic mice at normal glycemia over a
week after treatment with focused ultrasound (Figure 21c).
Kohane and co-workers244 developed an in situ cross-linking
hydrogel for repeated on-demand ultrasound-triggered drug
delivery. This injectable hydrogel composed of drug-containing
liposomes and gas-filled microbubbles presented a low baseline
rate of drug release and prolonged the ultrasound triggerability
for over 14 days. Another ultrasound-responsive hydrogel
invented by Mooney and co-workers245 was reported as a
promising DDS for sustained controlled release (Figure 22a).
With the disruption induced by ultrasound and self-healing of
ionically cross-linked hydrogels, the switch of drug release
correspondingly turned on and off (Figure 22b,c). Results
indicated a remarkable decrease of tumor size after daily
ultrasound treatment compared to the control group (Figure
22d). Similar polymers that can be ionically cross-linked are
possible candidates for ultrasonic drug delivery using this
approach. Grinstaff and co-workers246 prepared superhydropho-
bic meshes with poly(ε-caprolactone) (PCL) and poly(glycerol
monostearate-co-caprolactone) (PGC-C18) for ultrasonic drug
delivery. The air entrapped both at the material surface and
within the structure of the 3D meshes could be removed upon
treatment with HIFU, allowing cargo release from meshes.
During recent decades, numerous ultrasound-sensitive drug
carriers have been developed for various medical applications.
Compared to compressive/tensile and shear force-triggered drug
delivery systems, the ultrasound-activated method can realize
precise and repeatable dosage control. Meanwhile, the highly
selective region for treatment can further avoid side effects.
Despite this, the requirement for an external ultrasound source
still hardly satisfies the need for a convenient and practical
treatment.
Figure 21. (a) Schematic illustration of ultrasound-mediated insulin delivery system using a nanonetwork. (b) Schematic of regulating BGLs in a
noninvasive manner via ultrasonic therapy. (c) BGLs of STZ mice administrated with three cycles of ultrasound treatment. Solid columns indicate the
administration window, including 5 min anesthesia and 0.5 min FUS treatment. (d) Tunable ultrasound parameters that can affect insulin release rate.
Reprinted with permission from ref 243. Copyright 2014 Wiley−VCH.
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5. MAGNETIC FORCE-TRIGGERED DRUG DELIVERY
Unlike ultrasound, the magnetic field remotely exerts force only
on magnetoresponsive materials. Currently, most magnetic
materials are inorganic matter, including superparamagnetic
iron oxide or metals like cobalt and nickel.247 However, these
hard materials are limited for magnetic force-triggered DDS.
Usually, researchers combine magnetic nanoparticles with a
flexible polymer material to achieve magnetoresponsive proper-
ties.76 By integration with thermoresponsive materials, the
localized heating caused by magnetic particles under an
alternating current magnetic field can be used to realize
controlled drug release. In an alternative way, the magnetic
material integrated with flexible polymers is able to deform by
Figure 22.Ultrasound-triggered drug delivery from self-healing hydrogel. (a) Scheme of ultrasound-induced disruption and self-healing of (●) ionically
cross-linked hydrogel. (b) Release profiles of mitoxantrone triggered by ultrasound and diffusion. (c) Survival curves for mice implanted with tumors
after receiving no treatment (black), treatment with a mitoxantrone-laden gel but no ultrasound (red), or treatment with a combination of
mitoxantrone-laden gel and daily ultrasound treatment (blue). (d) Images of tumors explanted from mice. Reprinted with permission from ref 245.
Copyright 2014 U.S. National Academy of Sciences.
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stretching, compressing, or bending to release the drug on
demand upon exposure to a magnetic field.248
Ferrogel, obtained by association of a ferrofluid and a hydrogel,
was first reported as a magnetic force-responsive system by
Zrińyi et al. in 1996.248 They distributed monodomain magnetic
particles with a diameter of 10 nm in a polymeric flexible network
by adhesive forces. The resulting gel, namely ferrogel, had the
ability to generate strain under a nonuniform magnetic field,
leading to a controllable change in shape. Since then, a great deal
of work on magnetic field-controlled drug delivery has been
reported by taking advantage of the deformation of ferrogels
under a magnetic field.137,249−251 For instance, a poly(vinyl
alcohol) (PVA) hydrogel with Fe3O4 magnetic particles was
capable of accumulating drug when an external magnetic field
was applied.249,252 In contrast, the accumulated drug rapidly
diffused out of the ferrogel once themagnetic field was turned off.
Due to high water content in the ferrogel, effective
incorporation of hydrophobic drugs is limited.253 In order to
address this issue, Muhammed and co-workers254 applied
Pluronic copolymer [poly(ethylene oxide)−poly(propylene
oxide)−poly(ethylene oxide)] as a gelling material to
encapsulate hydrophobic drugs. Pluronic is a triblock copolymer
consisting of one poly(propylene oxide) (PPO) block and two
poly(ethylene oxide) (PEO) blocks. After incorporation of
indomethacin, a model hydrophobic drug, PPO segments can
form a hydrophobic core to entrap it. In vitro release experiments
showed that the release rate significantly increased upon applying
a magnetic field. Besides small molecular drugs, Mooney and co-
workers255 further applied the ferrogel as an active depot of
various cells to achieve on-demand cell delivery. Homogeneous
pores with suitable size for cell adhesion were prepared by
freezing ferrogels at a specific temperature (Figure 23a). Unlike
nanoporous ferrogel, the resulting macroporous gel showed
reversible deformation at a compressive strain of 80% (Figure
23b). A larger deformation was also achieved in macroporous
ferrogel under the same magnetic field (Figure 23c,d). Cell-
binding peptides were further covalently conjugated onto the
polymer to support cell adhesion and viability. The results of in
vitro and in vivo tests indicated human dermal fibroblasts or
mouse mesenchymal stem cells could be released under external
magnetic stimulation. In particular, multiple stimulation
parameters, including the strength of external magnetic field,
frequency of stimulation, and number of cycles, are tunable to
control the cell release in this delivery system.
In addition, an oscillating or alternating magnetic field (AMF)
can cause vibration of magnetic particles. By taking advantage of
this phenomenon, Hu et al.256 designed a drug reservoir with a
magnetism-sensitive shell. A fluorescent dye was encapsulated in
the silica core as a model drug, with a thin layer of
poly(vinylpyrrolidone) (PVP)/Fe3O4 coating on the surface
(Figure 24). The core/shell nanosphere was stable in aqueous
solution with no significant dye release after 24 h. Once exposed
Figure 23. (a) Hierarchical structure of macroporous ferrogels. Ferrogels with different pore sizes were prepared by freezing gels at different
temperatures. (b) Stress vs strain curves for nanoporous and macroporous ferrogels subjected to compression tests. (c) Shape change in (top)
nanoporous ferrogel and (bottom) macroporous ferrogel when subjected to a vertical magnetic field. (d) SEM images of a freeze-dried macroporous
ferrogel in the undeformed and deformed states. (Scale bar 500 μm) Reprinted with permission from ref 255. Copyright 2011 U.S. National Academy of
Sciences.
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to a high-frequency AMF (50 kHz) for 5 min, a large amount of
preload dye diffused out to surrounding solution, as a result of
enlarged nanocrevices on the shell lattice structure caused by
vibration. With a shorter exposure (60 s), the physical
deformation is reversible; the Fe3O4 shell could return to intact
morphology and prevent dye diffusion for repeatable drug
release, while a long-term AMF could permanently damage the
magnetic shell since it received sufficient amounts of (vigorous)
energy to rupture the thin shell. In vitro cell studies illustrated
enhanced cell uptake efficiency in a remote-controlled manner.
Besides controlled drug release, the external magnetic force can
also enhance local tumor accumulation of therapeutic agents to
achieve higher cancer therapy efficacy. Liu and co-workers257−259
demonstrated that drug-loaded iron oxide nanoparticles
circulating in the blood could be guided and attracted to tumor
regions by external magnetic field. Compared to passive tumor-
targeting strategies like enhanced permeability and retention
(EPR), this active magnetic force-guided method showed higher
tumor accumulation efficiency and thus better tumor treatment
efficacy.
In these reports, the application of external magnetic force
provides an enhanced magnetic guided and controlled strategy
for drug delivery. For future clinical application, a three-
dimensional guidance and manipulation technology may further
help to increase precise dosage control and enhance therapy
efficiency.
6. CONCLUSIONS AND FUTURE PERSPECTIVES
In summary, distinct mechanisms of mechanical actuation can
trigger mechanical stimuli-responsive DDS for a variety of
applications, ranging from enhancing intracellular transfection to
assisting therapy of cancer, diabetes, and cardiovascular diseases.
We anticipate this simple and effective stimulus can further offer
a generic platform broadly applicable to a multitude of disease
treatments. For instance, stretch-induced DDS can be utilized to
deliver antibacterial agents, anticancer drugs, or growth factors,
which can locally generate anti-inflammation effects, suppress
tumor growth, or repair tissue in a self-administered manner;
while the shear-sensitive DDS can serve as personalized
medication for cardiovascular patients owing to its “intelligent”
localization function. Moreover, ultrasound can readily combine
imaging and drug delivery to achieve on-demand theranos-
tics.260−263 Drug release could also be monitored dynamically by
the imaging modality. When it comes to magnetic field-mediated
activation, treatment efficacy could be further enhanced by drug
accumulation in the target site, induced by themagnetic field, and
promoted drug release with repeated dosing by remote control.
Regarding clinical translation, more efforts are needed to
further improve most mechanical force-triggered DDS.264,265
First of all, it is still challenging to realize precise control of drug
dosage. Due to a relatively complicated combination of passive
release and dynamically triggered release, it is difficult to regulate
the released dosage in a repeatable manner, which becomes even
more challenging for long-term administration in a physiological
environment. A delivery system with confined drug amounts or
with a “rechargeable” mechanism could potentially avoid the risk
of side effects due to overdose. Second, for shear-sensitive DDS,
how to prolong the circulation time by modifying the surface and
how to enhance specific delivery by using targeted ligands are
two of the main difficulties that need to be addressed. More
details related to the dynamic flow behavior of the drug carrier
under shear flow should be taken into account in understanding
the performance and responsiveness of DDS. Third, from the
perspective of fundamental study, further detailed investigation
of the mechanism inside mechanoresponsive systems would help
improve treatment performance. For example, the mechanism is
still ambiguous between sonoporation and cellular interac-
tions.266 A more comprehensive understanding could allow
optimal use of the biological implications in ultrasonic drug
delivery. Last but not least, there is no consensus on parameter
settings for either ultrasound- or stretch-assisted DDS. To
achieve patient-centered medications,267 systematic tests and
adjustments could be indispensable. Alternatively, wearable
devices268−270 or implanted wireless biomedical chips271−273
that can dynamically monitor physiological signals could be
further integrated in the mechanoresponsive DDS to enhance
the performance.
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Figure 24. Core/single-crystal-shell nanosphere. (a) Schematic of high-
frequency magnetic field (HFMF)-induced cell structure variation. (b)
TEM and XRD images show (I) reversible change of nanofaults under
short-term field exposure and (II) permanent rupture of the thin shell
under long-term exposure. Reprinted with permission from ref 256.
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